VACCINEX, INC. Files 10-K for Fiscal Year Ended December 31, 2023

Ticker: VCNX · Form: 10-K · Filed: Apr 2, 2024 · CIK: 1205922

Vaccinex, Inc. 10-K Filing Summary
FieldDetail
CompanyVaccinex, Inc. (VCNX)
Form Type10-K
Filed DateApr 2, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $750,000, $3 million
Sentimentneutral

Sentiment: neutral

Topics: 10-K, VACCINEX, Financials, Warrants, Private Placement

TL;DR

<b>VACCINEX, INC. filed its 2023 10-K, detailing financial performance and significant corporate actions including multiple private placements and warrant transactions.</b>

AI Summary

VACCINEX, INC. (VCNX) filed a Annual Report (10-K) with the SEC on April 2, 2024. VACCINEX, INC. filed its annual 10-K report for the fiscal year ending December 31, 2023. The filing details financial activities and business operations for the period. Key events include private placements of common stock and warrants in March 2023 and September 2023. Subsequent events noted are a private placement of common and pre-funded warrants on February 6, 2024, and a public warrant transaction on March 27, 2024. The company is involved in the pharmaceutical preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking VACCINEX, INC., this filing contains several important signals. The 10-K filing provides a comprehensive overview of VACCINEX's financial health and strategic moves throughout 2023, offering investors insight into the company's trajectory. The inclusion of subsequent events like the February 2024 warrant placement signals ongoing financing activities and potential shifts in capital structure post-fiscal year-end.

Risk Assessment

Risk Level: medium — VACCINEX, INC. shows moderate risk based on this filing. The company's financial disclosures are limited in this extract, making a full assessment of its financial health challenging. However, the mention of multiple private placements and warrant transactions suggests ongoing capital raising activities, which can be indicative of funding needs.

Analyst Insight

Investors should closely examine the full 10-K for detailed financial statements, management's discussion and analysis, and risk factors to understand VACCINEX's financial position and future prospects.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Reported period)
  • 2024-04-02 — Filing Date (Date of submission)
  • 2022-11-18 — Private Placement Date (November Two Thousand Twenty Two Private Placement)
  • 2023-03-30 — Private Placement Date (March Two Thousand Twenty Three Private Placement)
  • 2023-09-20 — Private Placement Date (September Two Thousand Twenty Three Private Placement)
  • 2024-02-06 — Subsequent Event Date (February Two Thousand Twenty Four Private Placement)
  • 2024-03-27 — Subsequent Event Date (Public Warrants Transaction)

Key Players & Entities

  • VACCINEX, INC. (company) — Filer name
  • 2023-12-31 (date) — Fiscal year end
  • 2024-04-02 (date) — Filing date
  • ROCHESTER (location) — Business address city
  • NY (location) — Business address state
  • 14620 (postal_code) — Business address zip
  • 585-271-2700 (phone_number) — Business phone
  • PHARMACEUTICAL PREPARATIONS (industry) — Standard Industrial Classification

FAQ

When did VACCINEX, INC. file this 10-K?

VACCINEX, INC. filed this Annual Report (10-K) with the SEC on April 2, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by VACCINEX, INC. (VCNX).

Where can I read the original 10-K filing from VACCINEX, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by VACCINEX, INC..

What are the key takeaways from VACCINEX, INC.'s 10-K?

VACCINEX, INC. filed this 10-K on April 2, 2024. Key takeaways: VACCINEX, INC. filed its annual 10-K report for the fiscal year ending December 31, 2023.. The filing details financial activities and business operations for the period.. Key events include private placements of common stock and warrants in March 2023 and September 2023..

Is VACCINEX, INC. a risky investment based on this filing?

Based on this 10-K, VACCINEX, INC. presents a moderate-risk profile. The company's financial disclosures are limited in this extract, making a full assessment of its financial health challenging. However, the mention of multiple private placements and warrant transactions suggests ongoing capital raising activities, which can be indicative of funding needs.

What should investors do after reading VACCINEX, INC.'s 10-K?

Investors should closely examine the full 10-K for detailed financial statements, management's discussion and analysis, and risk factors to understand VACCINEX's financial position and future prospects. The overall sentiment from this filing is neutral.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-04-02: Filing Date — Date the 10-K was officially submitted to the SEC.
  • 2024-02-06: Subsequent Event — Private placement of common and pre-funded warrants.

Filing Stats: 4,465 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-04-01 20:43:21

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
  • $750,000 — r 2019, we announced a funding grant of $750,000 from the Alzheimer's Association and an
  • $3 million — investment in our common stock of up to $3 million from the Alzheimer's Drug Discovery Fou

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 50 Item 1B. Unresolved Staff Comments 75 Item 1C. Cybersecurity 75 Item 2.

Properties

Properties 76 Item 3.

Legal Proceedings

Legal Proceedings 76 Item 4. Mine Safety Disclosures 76 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 77 Item 6. Reserved 77 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 78 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 85 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 85 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85 Item 9A.

Controls and Procedures

Controls and Procedures 85 Item 9B. Other Information 86 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 86 PART III Item 10. Directors, Executive Officers and Corporate Governance 87 Item 11.

Executive Compensation

Executive Compensation 89 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 93 Item 13. Certain Relationships and Related Transactions, and Director Independence 95 Item 14. Principal Accounting Fees and Services 97 PART IV Item 15. Exhibits, Financial Statement Schedules 99 Item 16. Form 10-K Summary 101

Signatures

Signatures 102 i PAR T I

B usiness

Item 1. B usiness. Overview We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We are leveraging our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer's disease, or AD, head and neck cancer, and pancreatic cancer. Additionally, third party investigators are studying pepinemab in clinical trials in breast cancer, as well as in "window of opportunity" studies in other indications, including head and neck cancer, and melanoma. We have developed multiple proprietary platform technologies and are developing product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies. We employ our proprietary platform technologies, including through our work with our academic collaborators, to identify potential product candidates for sustained expansion of our internal product pipeline and to facilitate strategic development and commercial partnerships. Our lead platform technologies include our SEMA4D antibody platform and our ActivMAb antibody discovery platform. Our lead product candidate, pepinemab, is currently in clinical development for the treatment of Alzheimer's disease, head a

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.